Journal Mobile Options
Table of Contents
Vol. 54, No. 3, 2009
Issue release date: August 2009
Ann Nutr Metab 2009;54:197–201

Short-Term Low Calorie Diet Intervention Reduces Serum Advanced Glycation End Products in Healthy Overweight or Obese Adults

Gugliucci A. · Kotani K. · Taing J. · Matsuoka Y. · Sano Y. · Yoshimura M. · Egawa K. · Horikawa C. · Kitagawa Y. · Kiso Y. · Kimura S. · Sakane N.
aGlycation, Oxidation and Disease Laboratory, Touro University-California, Vallejo, Calif., USA; bDivision of Preventive Medicine, Clinical Research Institute for Endocrine and Metabolic Disease, National Hospital Organization Kyoto Medical Center, Kyoto, cInstitute for Health Care Science, Suntory Ltd. Research Center, Osaka, dDepartment of Laboratory Medicine and Central Clinical Laboratory, Showa University Northern Yokohama Hospital, Yokohama, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Obesity is a metabolic and cardiovascular risk factor. A low calorie diet (LCD) is one of the treatment modalities for weight loss. Serum advanced glycation end products (AGEs) are linked to increased atherogenicity and inflammation in diseases such as diabetes and renal failure. Obesity has an inflammatory component, but interestingly there are no studies on serum AGE levels in obesity or on the effects of LCD as a therapeutic measure on these markers of glycation. Aim: We hypothesized that weight loss by caloric restriction has a beneficial effect on serum AGE levels. We investigated the prospective effects of a sole LCD intervention for weight loss on serum AGEs in a cohort of overweight and non-morbidly obese but otherwise healthy subjects. Methods: A total of 37 Japanese subjects (30 females, 7 males, mean age 48.2 ± 9.3 years) with a mean BMI of 28.3 ± 3.2 participated in this study. During the intervention period of 2 months, they were placed on an LCD (Diet’s™; 5,023 kJ/day) with meal replacement every dinner. The following data were evaluated pre- and post-intervention: AGEs, BMI, waist circumference, blood pressure, serum glucose, cholesterol, triglycerides, HDL- and LDL- cholesterol. Results and Discussion: After the intervention, BMI levels were clearly reduced by 6.3% (p < 0.001), waist circumference by 5.7% (p < 0.002) and triglycerides by 11.9 % (p < 0.002). At baseline, AGEs levels were 63 ± 11 AU for obese subjects and 63 ± 14 for control subjects (not significant). After intervention, AGEs were reduced by 7.21% (range 0–35%, p < 0.001). The percent change in AGEs was significantly and positively correlated with that of triglycerides (r = 0.42, p < 0.009), waist circumference (r = 0.40, p < 0.011), and BMI (r = 0.42, p < 0.007). We show for the first time that serum AGEs can be reduced by an LCD intervention on weight loss, a change that correlates with the reduction in triglycerides. This may plausibly be a reflection of a reduction in glycation/lipoxidation due to the caloric restriction and its metabolic consequences, or it may be due to the decreased intake of food containing glycotoxins, or a combination of both.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Haffner SM: Relationship of metabolic risk factors and development of cardiovascular disease and diabetes. Obesity 2006;14:S121–S127.

    External Resources

  2. Shin MJ, Hyun YJ, Kim OY, Kim JY, Jang Y, Lee JH: Weight loss effect on inflammation and LDL oxidation in metabolically healthy but obese (MHO) individuals: low inflammation and LDL oxidation in MHO women. Int J Obes 2006;30:1529–1534.
  3. Monnier VM, Kohn RR, Cerami A: Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci USA 1984;81:583–587.
  4. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW: Formation of pentosidine during nonenzymatic browning of proteins by glucose: identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 1991;266:11654–11660.
  5. Csiszar A, Ungvari ZI: Endothelial dysfunction and vascular inflammation in type II diabetes: interaction of AGE/RAGE and TNF-α signaling. Am J Physiol Heart Circ Physiol 2008;295:H475–H476.
  6. Soro-Paavonen A, Watson AM, Li J, Paavonen K, Koitka A, Calkin AC: Rage deficiency attenuates the development of atherosclerosis in diabetes. Diabetes 2008;57:2461–2469.
  7. Gugliucci A, Bendayan M: Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells. Diabetologia 1996;39:149–160.
  8. Rabbani N, Sebekova K, Sebekova K, Heidland A, Thornalley PJ: Accumulation of free adduct glycation, oxidation, and nitration products follows acute loss of renal function. Kidney Int 2007;72:1113–1121.
  9. Vlassara H, Striker G: Glycotoxins in the diet promote diabetes and diabetic complications. Curr Diab Rep 2007;7:235–241.
  10. Uribarri J, Peppa M, Cai W, Goldberg T, Lu M, He C, Vlassara H: Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol 2003;14:728–731.
  11. Diamanti-Kandarakis E, Katsikis I, Piperi C, Alexandraki K, Panidis D: Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 2007;66:103–109.
  12. Li SY, Liu Y, Sigmon VK, McCort A, Ren J: High-fat diet enhances visceral advanced glycation end products, nuclear O-Glc-Nac modification, p38 mitogen-activated protein kinase activation and apoptosis. Diabetes Obes Metab 2005;7:448–454.
  13. Hill JO, Wyatt H: Outpatient management of obesity: a primary care perspective. Obes Res 2002;2:S124–S130.

    External Resources

  14. Berkel LA, Poston WS, Reeves RS, Foreyt JP: Behavioral interventions for obesity. J Am Diet Assoc 2005;105:S35–S43.
  15. Barnard RJ: Effects of life-style modification on serum lipids. Arch Intern Med 1991;151:1389–1394.
  16. Gugliucci A, Mehlhaff K, Kinugasa E, Ogata H, Hermo R, Schulze J, Kimura S: Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlation with low molecular AGE adduct clearance. Clin Chim Acta 2007;377:213–220.
  17. Clynes R, Moser B, Yan SF, Ramasamy R, Herold K, Schmidt AM: Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response. Curr Mol Med 2007;7:743–751.
  18. Norata GD, Garlaschelli K, Grigore L, Tibolla G, Raselli S, Redaelli L: Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. Nutr Metab Cardiovasc Dis 2008;19:129–139. DOI: 10.1016/j.numecd.2008.03. 004.
  19. Vander Jagt DL: Methylglyoxal, diabetes mellitus and diabetic complications. Drug Metabol Drug Interact 2008;23:93–124.
  20. Cai W, He JC, Zhu L, Chen X, Zheng F, Striker GE, Vlassara H: Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan. Am J Pathol 2008;173:327–336.
  21. Januszewski AS, Jenkins AJ, Baynes JW, Thorpe SR: Lipid-derived modifications of plasma proteins in experimental and human diabetes. Ann NY Acad Sci 2005;1043:404–412.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50